Microsphere as a novel strategy for the long-term use of corticosteroids in asthma patients during the COVID-19 Pandemic

The use of corticosteroids during the (Coronavirus Disease 2019) COVID-19 has become a new concern. Corticosteroids are the main therapy in asthmatic patients with anti-inflammatory and immunosuppressant effects. Patients with the need for long-term use of corticosteroids, such as asthma patients, are aware of the risk from infection obtained by the side effect of long-term corticosteroid use. A Recent study has innovated a new drug delivery agent, called Microsphere that can specify the targeted therapy. This new therapy may potentially increase the treatment efficacy with the lesser side effects. Here we review a study that uses the Microsphere for delivering corticosteroids. Additional studies are warranted to support the use of Microspheres as novel drug delivery for asthma patients during the COVID-19 pandemic.